OBJECTIVE: To determine the incidence of salivary gland tumors in a population of a tertiary hospital in the State of Mexico, and to describe demographic variables. METHOD: An observational, cross-sectional and retrospective study of salivary gland tumors reported in a tertiary hospital in the State of Mexico in the period 2008-2019 is presented. RESULTS: A prevalence of 0.049% was found. There was no difference between sex in the studied population. Benign salivary gland tumors were the most frequent (86.7%). The age range most affected was 51-60 years. The most frequently found tumor was the pleomorphic adenoma, followed by Warthin's tumor. There was 13.33% of sialolipomas, and one myoepithelioma. There were no cases of sublingual gland tumors or minor salivary glands. CONCLUSION: Tumors of the major salivary glands are infrequent tumors; population cases from a central Mexican state and their demographic characteristics are presented to contribute to the information found in local and international literature.
OBJETIVO: Determinar la incidencia de los tumores de glándulas salivales en una población de un hospital de tercer nivel en el Estado de México y describir variables demográficas. MATERIAL Y MÉTODOS: Se presenta un estudio observacional, transversal y retrospectivo de los tumores de glándulas salivales reportados en un hospital de tercer nivel en el Estado de México en el periodo 2008-2019. RESULTADOS: Se encontró una prevalencia del 0.049%. No hubo diferencia entre sexos en la población afectada. Los tumores de glándulas salivales benignos fueron los más frecuentes (86.7%). El rango de edad mayormente afectado fue el de 51-60 años. El tumor más frecuentemente encontrado fue el adenoma pleomorfo, seguido por tumor de Warthin. Se presentó un 13.33% de sialolipomas y un mioepitelioma. No se presentó ningún caso de tumores de glándulas sublinguales ni glándulas salivales menores. CONCLUSIÓN: Los tumores de glándulas salivales mayores son tumores infrecuentes, se exponen casos de población de un Estado del centro de México y sus características demográficas para contribuir a la información encontrada en literatura local e internacional.
Salivary Gland Neoplasms , Humans , Adult , Middle Aged , Mexico/epidemiology , Tertiary Care Centers , Cross-Sectional Studies , Incidence , Retrospective Studies , Salivary Gland Neoplasms/epidemiology
Familial combined hyperlipidemia (FCHL) is the most prevalent primary dyslipidemia; however, it frequently remains undiagnosed and its precise definition is a subject of controversy. FCHL is characterized by fluctuations in serum lipid concentrations and may present as mixed hyperlipidemia, isolated hypercholesterolemia, hypertriglyceridemia, or as a normal serum lipid profile in combination with abnormally elevated levels of apolipoprotein B. FCHL is an oligogenic primary lipid disorder, which can occur due to the interaction of several contributing variants and mutations along with environmental triggers. Controversies surrounding the relevance of identifying FCHL as a cause of isolated hypertriglyceridemia and a differential diagnosis of familial hypertriglyceridemia are offset by the description of associations with USF1 and other genetic traits that are unique for FCHL and that are shared with other conditions with similar pathophysiological mechanisms. Patients with FCHL are at an increased risk of cardiovascular disease and mortality and have a high frequency of comorbidity with other metabolic conditions such as type 2 diabetes, non-alcoholic fatty liver disease, steatohepatitis, and the metabolic syndrome. Management usually requires lipid-lowering therapy directed toward reducing cholesterol and triglyceride concentrations along with cardiovascular risk protection. In recent years, the number of research studies on FCHL has been decreasing, mainly due to a lack of recognition of its impact on disease burden and comorbidity and the complexity in identifying probands for studies. This creates areas of opportunity to develop research for FCHL in epidemiology, genetics, pathophysiology, therapeutics, and cardiovascular risk management, which are discussed in depth in this review. (REV INVEST CLIN. 2018;70:224-36).
Cardiovascular Diseases/prevention & control , Hyperlipidemia, Familial Combined/therapy , Lipids/blood , Animals , Apolipoproteins B/blood , Cardiovascular Diseases/etiology , Diagnosis, Differential , Humans , Hyperlipidemia, Familial Combined/complications , Hyperlipidemia, Familial Combined/physiopathology , Hyperlipoproteinemia Type IV/diagnosis , Risk Factors
